Home » Topics » BioWorld Science

BioWorld Science
RSS

Patients dosed in phase I/II trial of topical RECCE-327 for infected burn wounds

July 13, 2021

Immunic presents new preclinical and clinical data for IMU-935

July 13, 2021

Qixleef phase II protocol modifications approved

July 13, 2021

Prokineticin-2 as therapeutic target for prevention of neuronal death

July 13, 2021

Aptorum reports further interim phase I data on ALS-4

July 13, 2021

Identification of antivirulence compound ANT-3273 for P. aeruginosa infection

July 13, 2021

Dosing begins in phase I study of CB-010 in B-cell NHL

July 13, 2021

First patient treated in phase I study of INKmune in high-risk MDS

July 13, 2021

Hummingbird and MD Anderson collaborate to advance VISTA antagonist antibody, HMBD-002

July 13, 2021

EscharEx debridement agent demonstrates efficiency, safety in chronic wound study

July 13, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...